Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lessened by 683 Capital Management LLC

683 Capital Management LLC lessened its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 9.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,785,000 shares of the company's stock after selling 415,000 shares during the quarter. Wave Life Sciences comprises 2.9% of 683 Capital Management LLC's portfolio, making the stock its 2nd biggest holding. 683 Capital Management LLC owned approximately 2.48% of Wave Life Sciences worth $46,820,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in WVE. Price T Rowe Associates Inc. MD increased its position in shares of Wave Life Sciences by 63.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock valued at $63,074,000 after purchasing an additional 1,972,262 shares during the last quarter. Loomis Sayles & Co. L P bought a new position in Wave Life Sciences during the fourth quarter valued at $20,545,000. Vanguard Group Inc. increased its position in Wave Life Sciences by 10.2% during the fourth quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company's stock valued at $39,368,000 after acquiring an additional 294,956 shares during the last quarter. Emerald Advisers LLC raised its stake in shares of Wave Life Sciences by 9.7% in the fourth quarter. Emerald Advisers LLC now owns 3,162,369 shares of the company's stock valued at $39,119,000 after acquiring an additional 280,859 shares during the period. Finally, Principal Financial Group Inc. bought a new stake in shares of Wave Life Sciences in the 4th quarter worth about $3,076,000. Institutional investors own 89.73% of the company's stock.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares in the company, valued at approximately $157,443.55. This trade represents a 39.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Paul Bolno sold 169,025 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the sale, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Trading Up 3.4 %

Shares of NASDAQ:WVE traded up $0.22 on Wednesday, reaching $6.63. The company had a trading volume of 746,136 shares, compared to its average volume of 1,253,405. The firm has a market capitalization of $1.02 billion, a PE ratio of -5.98 and a beta of -0.91. Wave Life Sciences Ltd. has a 52-week low of $4.25 and a 52-week high of $16.74. The firm's 50 day simple moving average is $8.02 and its 200-day simple moving average is $11.33.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.34. The company had revenue of $83.75 million during the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. As a group, equities research analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Wall Street Analyst Weigh In

WVE has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Wedbush initiated coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They set an "outperform" rating and a $18.00 price target for the company. Cantor Fitzgerald initiated coverage on Wave Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective on the stock. Jefferies Financial Group began coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 target price for the company. Finally, StockNews.com upgraded shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.17.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.